Earnings call transcript: Charles River Associates tops Q2 2026 forecasts

Charles River Associates reported Q2 fiscal 2026 revenue of $210.8M (+12.8% YoY), nearly 6% above the $198.9M forecast, and adjusted EPS of $2.16 (vs. $2.15 consensus). Profit growth outpaced sales, and the firm raised full-year 2026 revenue guidance to $805M–$820M (midpoint $812.5M, +$7.5M vs prior). Despite the beat, the stock fell 1.73% to $173.54 as the EPS surprise was small and investors may have been cautious around higher taxes and working-capital needs.

Analysis

The core read-through is that CRAI is not a generic “AI beneficiary”; it is selling complexity. AI is widening the attack surface in forensics, speeding up merger math in antitrust, and increasing demand for externalized expertise where internal teams can’t keep up. That favors the higher-quality expert-services platform names first — CRAI, then FCN/HURN as laggards if the cycle broadens — but CRAI’s mix is cleaner because growth is coming from multiple end-markets rather than one hot vertical. The market’s initial fade looks less like disbelief in demand and more like concern that cash conversion is deteriorating faster than reported earnings.

The near-term risk is balance-sheet optics, not revenue. Rising DSO and revolver usage can keep the multiple capped for 1-2 quarters even if fundamentals stay strong, especially with a higher effective tax rate compressing EPS leverage. Over 6-18 months, the bigger catalyst is whether management converts today’s lead flow into sustained headcount growth without breaking utilization; if they do, the current valuation should re-rate because this is a rare small-cap services compounder with both organic expansion and margin resilience. The main falsifier is a plateau in utilization or a reversal in lead conversion, which would tell us this quarter was simply timing pull-forward.

Contrarian view: consensus is probably underestimating how much of this revenue is sticky, high-margin, and early-cycle. If DOJ merger reviews become more targeted, the economic expert gets pulled in earlier, which can actually expand wallet share per transaction even if process length shortens. Separately, the market may be over-penalizing working-capital noise that is partially seasonal and talent-driven, while underappreciating that CRAI’s international growth suggests a structural share gain rather than macro beta.

Key Decisions for Investors

• Long CRAI on pullbacks into the low-170s with a 3-6 month horizon; thesis is continued revenue upgrades and eventual multiple recovery if DSO normalizes. Falsify if DSO stays >110 and Q3/Q4 guide does not inflect cash conversion.
• Pair: long CRAI / short FCN for 1-3 months if you want a quality-growth relative value expression. CRAI has more visible organic acceleration and AI/cyber optionality; FCN is more exposed to broader project-cycle slowness.
• Use a call spread rather than outright stock if entering before the next print: CRAI 3-6 month bullish call spread to express upside from guide credibility while limiting risk from working-capital headlines.
• Watchlist alert: if CRAI closes back above its post-earnings gap and management reiterates mid-single-digit headcount growth with stable utilization, add to position; if utilization slips below mid-70s, fade the move.